Adimab

Adimab is a private biotechnology company founded in 2007, headquartered in Lebanon, New Hampshire, with a west coast office in Mountain View, California. It operates a proprietary yeast-based antibody discovery and engineering platform that combines fully human synthetic and immune libraries to generate specific, stable and developable IgGs, heavy-chain antibodies (HCAbs), multispecifics, T-cell engagers and T-cell receptors. Adimab deliberately runs no internal therapeutic pipeline, instead partnering with biopharma companies through funded discovery programs, platform transfer and non-exclusive program deals. The company reports more than 140 industry partnerships since 2009, 675+ therapeutic programs initiated, 90+ clinical programs and 6 commercial products. Adimab publishes no public developer API, SDK, developer portal or machine-readable API contract; its capabilities are delivered as laboratory discovery services and licensed platform transfer under partnership agreements.

Adimab is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Antibody Discovery, and Protein Engineering.

🌐 Visit website 📡 Source on GitHub

12.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1

0 APIs

CompanyBiotechnologyLife SciencesAntibody DiscoveryProtein EngineeringDrug DiscoveryPharmaceuticalsResearch Services

Kin Score

Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1

Composite quality — 12.0/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.9 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/adimab: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Contact

Contact

PressReleases

PressReleases

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 4

The organization behind the API

Website

Website

About

About

Careers

Careers

LinkedIn

Other 6

Properties that don't map to a standard resource type

Events

Resources

Publications

WhitePapers

Leadership

SecondaryMarket

Source (apis.yml)

aid: adimab
name: Adimab
description: Adimab is a private biotechnology company founded in 2007, headquartered in Lebanon, New Hampshire, with a west
  coast office in Mountain View, California. It operates a proprietary yeast-based antibody discovery and engineering platform
  that combines fully human synthetic and immune libraries to generate specific, stable and developable IgGs, heavy-chain
  antibodies (HCAbs), multispecifics, T-cell engagers and T-cell receptors. Adimab deliberately runs no internal therapeutic
  pipeline, instead partnering with biopharma companies through funded discovery programs, platform transfer and non-exclusive
  program deals. The company reports more than 140 industry partnerships since 2009, 675+ therapeutic programs initiated,
  90+ clinical programs and 6 commercial products. Adimab publishes no public developer API, SDK, developer portal or machine-readable
  API contract; its capabilities are delivered as laboratory discovery services and licensed platform transfer under partnership
  agreements.
url: https://raw.githubusercontent.com/api-evangelist/adimab/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
image: https://adimab.com/wp-content/uploads/2025/08/ADIMAB_LOGO.svg
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Biotechnology
- Life Sciences
- Antibody Discovery
- Protein Engineering
- Drug Discovery
- Pharmaceuticals
- Research Services
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/adimab-domain-security.yml
- type: LLMsTxt
  url: llms/adimab-llms.txt
- type: Website
  url: https://adimab.com/
- type: About
  url: https://adimab.com/about-us/
- type: Contact
  url: https://adimab.com/contact-us/
- type: Careers
  url: https://adimab.com/careers/open-positions/
- type: PressReleases
  url: https://adimab.com/news-events/press-releases/
- type: Events
  url: https://adimab.com/news-events/events/
- type: Resources
  url: https://adimab.com/resources/
- type: Publications
  url: https://adimab.com/resources/?_resources_type=publications
- type: WhitePapers
  url: https://adimab.com/resources/?_resources_type=white-papers
- type: PrivacyPolicy
  url: https://adimab.com/privacy-policy/
- type: TermsOfService
  url: https://adimab.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/adimab-llc/
- type: Leadership
  url: https://adimab.com/leadership/
- type: SecondaryMarket
  url: https://www.hiive.com/securities/adimab-stock
x-enrichment:
  date: '2026-08-02'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-api-surface:
  public_api: false
  checked: '2026-08-02'
  note: No developer portal, API documentation, OpenAPI/Swagger/AsyncAPI/GraphQL contract, MCP server, A2A agent card, /.well-known
    surface, or first-party SDK on npm/PyPI/RubyGems/crates.io. Adimab delivers antibody discovery as a laboratory service
    and licensed platform transfer, not as an API.